Galecto Biotech
Denmark - CopenhagenBiotechnology
Focus: Galecto is a Copenhagen-based biotech focused on galectin-targeting therapeutics across oncology, respiratory, gastroenterology, hematology, and infectious diseases. Founded in 2011, the company operates as a clinical-stage biotech with a differentiated platform approach to galectin inhibition.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Galecto Biotech
AI assessmentNot HiringNo open roles listed right now. Follow Galecto Biotech to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
10 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
GB1211
Safety and TolerabilityClinical Trials (1)
NCT03809052A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
Phase 1Help build intelligence for Galecto Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.